Filing Summary
Registrant: Priveterra Acquisition Corp. (proposed business combination partner of AEON Biopharma, Inc.)
Filing date and event period: February 6, 2023; Form 8-K, Item 8.01 (Other Events) and Item 9.01(d). The filing reports developments concerning the proposed AEON business combination and an extension of the SPAC’s deadline.
Business Context and Reporting Period
Priveterra is a special purpose acquisition company seeking to complete its previously disclosed business combination with AEON Biopharma. The filing supplements the December 22, 2022 definitive proxy statement and updates the timing and terms of the shareholder vote on extending the business-combination deadline.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit, operating cash flow, margins, balance-sheet debt, or other periodic financial statements.
- If approved, the sponsor or its designees will loan the lesser of $240,000 or $0.12 per public share outstanding and not redeemed, covering February 11 through May 11, 2023.
- If the AEON transaction remains incomplete after May 11, 2023, the sponsor may elect to loan, for each additional month through August 11, 2023, the lesser of $80,000 or $0.04 per public share outstanding.
- The loans will be non-interest-bearing and unsecured, documented by promissory notes, and repayable upon completion of an initial business combination.
- If no business combination is completed by August 11, 2023, the notes may be repaid only from funds outside the trust account or may be forfeited, eliminated, or forgiven.
Material Changes Versus Prior Disclosure
- The special meeting was postponed from February 6 to February 10, 2023, at 12:00 p.m. Eastern Time, via virtual webcast.
- The deadline for submitting redemption requests was extended from January 20 to February 8, 2023. Stockholders may also withdraw previously submitted redemption requests by February 8.
- The proposed extension date was clarified and amended from references to September 11, 2023 to August 11, 2023.
- The extension would move the business-combination deadline from February 11, 2023 to August 11, 2023.
- The sponsor contribution mechanism and potential liquidation consequences were disclosed as conditions to the proposed extension.
Guidance, Outlook, Risks, and Unusual Items
- Management is seeking additional time to complete the AEON business combination; completion remains subject to shareholder approval and other transaction conditions.
- If the extension proposal is not approved, no sponsor contribution will occur and the company may be required to liquidate and redeem its Class A common stock under its charter.
- The sponsor may elect not to make any required monthly contribution. In that event, the company is expected to liquidate as promptly as practicable.
- The filing notes that a 1% U.S. federal excise tax under the Inflation Reduction Act of 2022 could apply to redemptions or stock buybacks. Trust-account proceeds and related interest generally will not be used to pay such excise taxes or other applicable fees and taxes, except for franchise and income taxes.
- Forward-looking statements are subject to risks involving the proposed transaction, shareholder approval, financing, redemption levels, timing, liquidation, and other risks described in the proxy statement and related SEC filings.
Facts Investors Should Verify
- Whether stockholders approved the Extension Amendment Proposal at the February 10, 2023 special meeting.
- The number of public shares ultimately redeemed and the resulting trust-account balance.
- Whether the sponsor made the $240,000-or-$0.12-per-share contribution and any subsequent monthly contributions.
- Whether and when the AEON business combination was completed, amended, or terminated.
- The final liquidation deadline and the treatment of any sponsor promissory notes if the transaction was not completed.
- The potential impact of the federal excise tax on redemption proceeds and trust-account funds.